Cadila Healthcare gets FDA nod to sell generic anti-diabetic drug in US1 min read . Updated: 11 May 2016, 05:43 PM IST
Cadila will market glyburide in 1.25mg, 2.5mg and 5mg forms in the US
Hyderabad: Drug maker Cadila Healthcare Ltd said on Wednesday it has won approval from the US Food and Drug Administration (FDA) to market generic anti-diabetic glyburide tablets in the US.
The approval from the FDA allows Cadila to market the drug in 1.25 milligram (mg), 2.5mg and 5mg forms.
Glyburide will be produced at its formulations manufacturing facility at Baddi, Himachal Pradesh, Cadila said in a statement.
The Ahmedabad-based company said it has more than 100 approvals from FDA. Till now the group has filed over 280 abbreviated new drug applications (ANDAs) since it commenced the filing process in 2003-04, the company added.
Shares of Cadila dropped 0.14% to close at ₹ 322.85 on BSE, on a day when the benchmark Sensex declined 0.68% to end at 25,597.02 points.